[
    {
        "pregunta": "1. What are the key recommendations for perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty according to the 2022 American College of Rheumatology guideline?",
        "respuesta": "The key recommendations for perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty according to the 2022 American College of Rheumatology guideline include addressing disease modifying medications for adults with inflammatory arthritis and systemic lupus, as well as prioritizing medication management to decrease infection risk in patients with rheumatoid arthritis. The guideline also emphasizes shared decision-making processes with full consideration of the patient's preferences and risks.",
        "contexto": [
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty      32D6EF0B25CDA1FB80B29547C7367EA8 10.1002/acr.24893  This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  American College of Rheumatology      D7E914B32636437769C151DE0A277789 10.1002/acr.24893 Submitted for publication February 9, 2022; accepted in revised form April 7, 2022.  INTRODUCTION Advances in antirheumatic therapy have led to remarkable",
            "have rheumatoid arthritis (RA) in this guideline, which is a limitation but was beyond our scope, as questions regarding the timing of surgery in patients who have RA prioritize medication management to decrease infection risk, which was the focus of the updated 2022 ACR/AAHKS Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty This guideline has several strengths. The recommendations",
            "systemic inflammatory disease activity and are likely to be taking immunosuppressant medications at the time of surgery, the management of which was felt to be beyond the scope of this guideline. This was the focus of the 2022 American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty METHODS This",
            "guideline does not address arthroplasty for patients who have rheumatic diseases, as they were the focus of the recent ACR/AAHKS guideline for the perioperative management of antirheumatic medications in patients undergoing total hip and total knee arthroplasty A conditional recommendation means that the panel has inferred that the majority of informed patients would choose the recommended course of action, but that an appreciable minority would not. A shared decision-making process with full"
        ]
    },
    {
        "pregunta": "2. Why are all recommendations in the guideline considered conditional?",
        "respuesta": "All recommendations in the guideline are considered conditional because of the uncertainty regarding the balance of benefits and harms. This may be due to lower certainty evidence, sensitivity to individual patient preferences, or expected costs impacting the decision. Therefore, shared decision-making with the patient is emphasized to determine the best course of action based on their specific situation.",
        "contexto": [
            "may be made with very-low certainty evidence if the recommendation is considered benign, low cost, and without harms. A conditional recommendation is supported by lower certainty evidence, has uncertainty regarding the balance of benefits and harms, is sensitive to individual patient preferences, or has costs expected to impact the decision. Thus, conditional recommendations warrant shared decisionmaking with the patient. Notably, most evidence reviewed in this guideline is downgraded for",
            "of moderate-or high-quality rating of the evidence, and a conditional recommendation in the presence of very-low or low-quality evidence (although recommendations can also be conditional in the setting of moderate-quality evidence, and in certain circumstances strong in the face of low-quality evidence) Limitations of the guideline include the limited comparative evidence to inform selection of therapies (i.e., primary comparative benefit/efficacy and harms evidence) and the inability to",
            "or high certainty of evidence where the benefits consistently outweigh the risks, and, with only rare exceptions, an informed patient and his or her provider would be expected to reach the same decision. Conditional recommendations reflect scenarios for which the benefits and risks may be more closely balanced and/or only low certainty of evidence or no data are available. Recommendations in this guideline apply to patients with gout, except for a single recommendation regarding the use of ULT",
            "recommendation denotes uncertainty regarding the balance of benefits and harms, such as when the evidence quality is low or very low, or when the decision is sensitive to individual patient preferences, or when costs are expected to impact the decision. Thus, conditional recommendations refer to decisions in which incorporation of patient preferences is a particularly essential element of decision-making. Examples of each class of pharmacologic intervention addressed in the recommendations are",
            "an intervention clearly outweigh the harms (or vice versa); a conditional recommendation denotes uncertainty regarding the balance of benefits and harms, such as when the evidence certainty is low or very low, or when the decision is sensitive to individual patient preferences, or when costs are expected to impact the decision. Thus, conditional recommendations refer to decisions in which incorporation of patient preferences is a particularly essential element of decision-making. Scope"
        ]
    },
    {
        "pregunta": "3. Which disease-modifying antirheumatic drugs (DMARDs) are conditionally recommended to be continued through surgery for patients with RA, AS, PsA, JIA, or SLE undergoing elective THA or TKA?",
        "respuesta": "The disease-modifying antirheumatic drugs (DMARDs) conditionally recommended to be continued through surgery for patients with RA, AS, PsA, JIA, or SLE undergoing elective THA or TKA according to the 2022 American College of Rheumatology guideline include methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.",
        "contexto": [
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes",
            "<p>|Recommendation/strength of recommendation|Level of evidence|\n|---|---|\n|For patients with RA, AS, PsA, JIA, or all SLE undergoing THA or TKA, continuing the usual dosing of the following DMARDs through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.†|Low to moderate|",
            "management of DMARDs, biologics, and GCs for adult patients with RA, SpA including AS and PsA, JIA, and SLE undergoing elective THA or TKA. This guideline is intended for use by clinicians and patients and balances the risk of flares of disease when medications are withheld versus infection risk attributed to the medications when they are continued. This update adds new medications introduced and reviews the studies published since the 2017 ACR/AAHKS guideline that have informed our",
            "includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA. ***For patients with RA, AS, PsA, or all SLE for whom anti-rheumatic therapy was held prior to undergoing TJA, restarting the anti-rheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling,",
            "| Adults age ≥18 years diagnosed with RA, SpA, including AS and PsA, JIA, or SLE who are deemed to be appropriate surgical candidates, are undergoing elective THA or TKA, and who are receiving antirheumatic drug therapy at the time of surgery. |"
        ]
    },
    {
        "pregunta": "4. What is the recommendation for withholding biologics, including rituximab, prior to surgery for patients with RA, AS, PsA, or JIA undergoing elective THA or TKA?",
        "respuesta": "The recommendation for patients with RA, AS, PsA, or JIA undergoing elective THA or TKA is to withhold all biologics, including rituximab, prior to surgery and plan the surgery after the next dose is due. This recommendation is considered conditional and is based on low certainty evidence.",
        "contexto": [
            "|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended.|Low|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended.‡|Low|",
            "AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients",
            "and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four observational studies provided additional indirect evidence to the previous systematic literature review and found no relationship between the included drugs and the risk of postoperative infections, although the number of included cases and events were low For patients with RA, AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics,",
            "|For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally recommended.|Low|\n|For patients with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended.|Low|",
            "As noted in the previous guideline, the patient's rheumatologist should be consulted regarding medication management. A patient with severe SLE who has been stable for >6 months or who has a history of recurrent or severe infections might discontinue the medications in the perioperative period. For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended. In the prior guideline,"
        ]
    },
    {
        "pregunta": "5. How should glucocorticoid therapy be managed for patients with RA, AS, PsA, or SLE undergoing THA or TKA?",
        "respuesta": "For patients with RA, AS, PsA, or SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, the 2022 American College of Rheumatology guideline recommends continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery. This recommendation is considered conditional and is based on available evidence.\n\nIf you have any more specific questions related to this topic or need further details, feel free to ask.",
        "contexto": [
            "|For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended.|Low|</p>",
            "management of DMARDs, biologics, and GCs for adult patients with RA, SpA including AS and PsA, JIA, and SLE undergoing elective THA or TKA. This guideline is intended for use by clinicians and patients and balances the risk of flares of disease when medications are withheld versus infection risk attributed to the medications when they are continued. This update adds new medications introduced and reviews the studies published since the 2017 ACR/AAHKS guideline that have informed our",
            "is a lack of a comparator group in the included studies Low For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended. surgery, although patients receiving intravenous abatacept within 2 weeks of surgery (one-half of a dosing interval) had a numerically",
            "doses of GCs on the day of surgery is conditionally recommended. This recommendation is unchanged from the previous guideline, with 2 new studies considered. One study found no significant association of supraphysiologic (\"stress dose\") GC doses with adverse events in SLE patients undergoing THA or TKA, but the sizes of the patient groups were small DISCUSSION We have updated the 2017 ACR/AAHKS guideline for the perioperative management of DMARDs, biologics, and GCs for adult patients with RA,",
            "rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative medication management remains unknown, but antirheumatic therapy is a readily modifiable risk factor for infection, whereas other risk factors for adverse outcomes, including disease activity or severity or longterm glucocorticoid (GC) use, may not be modifiable Given the increased infection risk seen in patients with IA and patients with SLE"
        ]
    },
    {
        "pregunta": "6. What is the updated recommendation for withholding tofacitinib, baricitinib, and upadacitinib prior to surgery for patients with RA, AS, PsA, or JIA undergoing THA or TKA?",
        "respuesta": "The updated recommendation for withholding tofacitinib, baricitinib, and upadacitinib prior to surgery for patients with RA, AS, PsA, or JIA undergoing THA or TKA is to withhold these medications for at least 3 days before the surgery. This recommendation was changed from the prior guideline, where tofacitinib was previously recommended to be withheld for 7 days before surgery, but new trial data led to the change to 3 days.",
        "contexto": [
            "|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended.|Low|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended.‡|Low|",
            "(see Table 2 For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended. This conditional recommendation was changed from the prior guideline. For the previous guideline, while the short serum half-life of tofacitinib was known, concern for a longer duration of the immune effect prompted the recommendation to withhold tofacitinib for 7 days prior to surgery. The new",
            "AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients",
            "to withhold tofacitinib for 7 days prior to surgery. The new recommendation was informed by trial data demonstrating rapid increases in disease activity after interrupting tofacitinib therapy, suggesting a rapid reversal of the immunosuppressive effects, so the recommendation was changed to withhold tofacitinib for 3 days prior to surgery For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine,",
            "and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four observational studies provided additional indirect evidence to the previous systematic literature review and found no relationship between the included drugs and the risk of postoperative infections, although the number of included cases and events were low For patients with RA, AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics,"
        ]
    },
    {
        "pregunta": "7. What medications are conditionally recommended to be withheld for patients with SLE (not severe) undergoing THA or TKA?",
        "respuesta": "The medications conditionally recommended to be withheld for patients with SLE (not severe) undergoing THA or TKA according to the 2022 American College of Rheumatology guideline include mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, tacrolimus, belimumab, and rituximab.",
        "contexto": [
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes",
            "AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients",
            "|For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally recommended.|Low|\n|For patients with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended.|Low|",
            "<p>|Recommendation/strength of recommendation|Level of evidence|\n|---|---|\n|For patients with RA, AS, PsA, JIA, or all SLE undergoing THA or TKA, continuing the usual dosing of the following DMARDs through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.†|Low to moderate|",
            "includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA. ***For patients with RA, AS, PsA, or all SLE for whom anti-rheumatic therapy was held prior to undergoing TJA, restarting the anti-rheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling,"
        ]
    },
    {
        "pregunta": "8. What is the recommendation for patients with severe SLE undergoing THA or TKA regarding the continuation of belimumab and rituximab?",
        "respuesta": "For patients with severe SLE undergoing THA or TKA, the recommendation is to continue belimumab and plan surgery in the last month of the dosing cycle of rituximab. This recommendation is considered conditional.",
        "contexto": [
            "As noted in the previous guideline, the patient's rheumatologist should be consulted regarding medication management. A patient with severe SLE who has been stable for >6 months or who has a history of recurrent or severe infections might discontinue the medications in the perioperative period. For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended. In the prior guideline,",
            "with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended. This recommendation is unchanged from the prior guideline. Patients with SLE that is not severe would not be at risk for permanent organ damage should they flare. In addition, nonsevere SLE patients could be followed up closely after surgery, and an intervention could be made to treat a flare as needed. Patients with frequent flares or SLE that is",
            "|For patients with severe SLE who have been deemed appropriate to undergo THA or TKA, continuing the usual dose of mycophenolate mofetil, mycophenolic acid (Myfortic), azathioprine, mizoribine, cyclosporine, or tacrolimus, anifrolumab, and voclosporin through surgery is conditionally recommended.‡|Low|\n|For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended.‡|Low|",
            "<p>|Recommendation/strength of recommendation|Level of evidence|\n|---|---|\n|For patients with RA, AS, PsA, JIA, or all SLE undergoing THA or TKA, continuing the usual dosing of the following DMARDs through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.†|Low to moderate|",
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes"
        ]
    },
    {
        "pregunta": "9. When should antirheumatic therapy be restarted for patients with RA, AS, PsA, or SLE who underwent total joint arthroplasty?",
        "respuesta": "Antirheumatic therapy should be restarted for patients with RA, AS, PsA, or SLE who underwent total joint arthroplasty once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection, which typically occurs around 14 days post-surgery. This recommendation is conditionally recommended according to the 2022 American College of Rheumatology guideline.",
        "contexto": [
            "|For patients with RA, AS, PsA, or all SLE for whom antirheumatic therapy was withheld prior to undergoing TJA, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection, which is typically ~14 days, is conditionally recommended.|Low|",
            "<p>§ Drug added for 2022 update.</p>\n\n<p>¶ For patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or all SLE for whom antirheumatic therapy was withheld prior to undergoing total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/staples are out, there is no signiﬁcant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection, which is typically ~14 days.</p>",
            "for the use of belimumab in severe SLE including nephritis, as well as increased comfort with belimumab among clinicians and patients given its widespread use, low infection risk described in clinical trials, and inclusion in SLE treatment guidelines For patients with RA, AS, PsA, or all SLE for whom antirheumatic therapy was withheld prior to undergoing total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/ staples are out,",
            "complications led to delays in restarting therapy Patients and their physicians might elect longer periods of not taking medication given a history of prior severe infections or a history of a prior prosthetic joint infection. For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving GCs for their rheumatic condition, continuing their current daily dose of GCs rather than administering supraphysiologic doses of GCs on the day of surgery is conditionally recommended. This",
            "As noted in the previous guideline, the patient's rheumatologist should be consulted regarding medication management. A patient with severe SLE who has been stable for >6 months or who has a history of recurrent or severe infections might discontinue the medications in the perioperative period. For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended. In the prior guideline,"
        ]
    },
    {
        "pregunta": "10. What is the recommendation for managing glucocorticoid therapy on the day of surgery for patients with RA, AS, PsA, or SLE undergoing THA or TKA?",
        "respuesta": "For patients with RA, AS, PsA, or SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, the 2022 American College of Rheumatology guideline recommends continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery. This recommendation is considered conditional and is based on available evidence.",
        "contexto": [
            "|For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended.|Low|</p>",
            "is a lack of a comparator group in the included studies Low For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended. surgery, although patients receiving intravenous abatacept within 2 weeks of surgery (one-half of a dosing interval) had a numerically",
            "doses of GCs on the day of surgery is conditionally recommended. This recommendation is unchanged from the previous guideline, with 2 new studies considered. One study found no significant association of supraphysiologic (\"stress dose\") GC doses with adverse events in SLE patients undergoing THA or TKA, but the sizes of the patient groups were small DISCUSSION We have updated the 2017 ACR/AAHKS guideline for the perioperative management of DMARDs, biologics, and GCs for adult patients with RA,",
            "complications led to delays in restarting therapy Patients and their physicians might elect longer periods of not taking medication given a history of prior severe infections or a history of a prior prosthetic joint infection. For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving GCs for their rheumatic condition, continuing their current daily dose of GCs rather than administering supraphysiologic doses of GCs on the day of surgery is conditionally recommended. This",
            "includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA. ***For patients with RA, AS, PsA, or all SLE for whom anti-rheumatic therapy was held prior to undergoing TJA, restarting the anti-rheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling,"
        ]
    }
]